值得注意的是，启明医疗此前宣布，集团于近日已就Cardiovalve经导管三尖瓣置换系统正式向欧洲公告 机构递交CE MDR认证的全部申请资料，标志着该产品在欧洲市场的准入进程迈出关键一步，也意味着 启明医疗在已成熟的主瓣、肺瓣产品线基础上，进一步完善了三尖瓣治疗矩阵。 智通财经APP获悉，启明医疗-B(02500)尾盘涨超10%，截至发稿，涨9.8%，报3.36港元，成交额1376.76 万港元。 消息面上，堃博医疗拟以总代价1500万美元，向启明医疗收购德晋医疗1.05%股权。启明医疗表示，作 为被投资公司的少数财务投资者，出售事项为本集团变现其投资的适当机会：透过剥离非核心业务投 资，本集团将能够加强其现金流，改善其营运资金状况，提升整体财务灵活性，并促进资源重新分配至 其核心业务。 ...

Core Viewpoint - The stock of Qiming Medical-B (02500) rose over 10% in late trading, currently up 9.8% at HKD 3.36, with a trading volume of HKD 13.76 million [1] Group 1: Investment Activity - Kunbo Medical plans to acquire a 1.05% stake in Qiming Medical for a total consideration of USD 15 million [1] - Qiming Medical stated that the sale represents an appropriate opportunity to monetize its investment as a minority financial investor [1] Group 2: Financial Strategy - By divesting non-core business investments, Qiming Medical aims to strengthen its cash flow, improve its working capital position, enhance overall financial flexibility, and facilitate resource reallocation to its core business [1] Group 3: Product Development - Qiming Medical has submitted all application materials for CE MDR certification of the Cardiovalve transcatheter tricuspid valve replacement system to the European notification agency, marking a significant step in the product's market entry process in Europe [1] - This development further enhances Qiming Medical's treatment matrix for tricuspid valves, building on its established mitral and pulmonary valve product lines [1]

Group 1 - Haixi New Drug (02637) rose nearly 5%, being a commercial-stage pharmaceutical company with integrated R&D, production, and sales capabilities, and a pipeline of innovative drugs under development [1] - Paige Biopharma-B (02565) increased over 4.1%, with cornerstone investors holding a total of 9.5845 million H shares, accounting for approximately 3.43% of the company's total issued H shares [1] - Naxin Micro (02676) surged over 5% to reach a new high of 118.4 HKD, operating under a fabless model focused on chip R&D and design, outsourcing wafer manufacturing and most packaging testing [1] - Huaxin Building Materials (06655) rose 1.46%, with a major shareholder planning to increase its A-share holdings by no less than 200 million RMB and no more than 400 million RMB within six months [1] Group 2 - Dairy stocks saw an uptick, with Modern Farming (01117) rising 6.21% and Youran Dairy (09858) increasing 6.29%, following the Ministry of Commerce's announcement of temporary countervailing measures against EU dairy imports [2] - Gakos-B (01167) rose over 2.7% after announcing a collaboration with AstraZeneca on its self-developed Pan-KRAS inhibitor JAB-23E73 [2] - Junda Co. (02865) increased over 4.1% after announcing a strategic investment in Shangyi Optoelectronics, focusing on perovskite battery technology applications in space energy [2] - Qiming Medical-B (02500) rose nearly 6% after submitting all application materials for CE MDR certification of its Cardiovalve system in Europe [2] Group 3 - Brain Dynamics-B (06681) saw a slight increase of 0.32%, participating in a national major science and technology project focused on the prevention and treatment of cancer and cardiovascular diseases [3] - Hesai Technology (02525) rose over 3.3% after announcing a strategic partnership with Meituan drones for mass production of its second-generation solid-state lidar [4] Group 4 - Hut8 (HUT.US) continued to rise by 4.13%, with a total increase of 37% over three trading days, following an upgrade of its target price to 85 USD by StoneX [5] - Unusual Machines (UMAC.US) surged 9.24%, with a total increase of 45% over three trading days, after receiving a 3.75 million USD order from Performance Drone Works [5] - Hycroft Mining (HYMC.US) opened with a 10.69% increase, having risen 460% since September, due to successful exploration drilling confirming high-grade silver continuity [6] - Sony (SONY.US) rose 2.1% after acquiring a 41% stake in Peanuts Holdings for 630 million CAD, which holds the rights to the Peanuts comic [7] - Novo Nordisk (NVO.US) increased by 7.3% after the FDA approved its first oral GLP-1 weight loss drug, Wegovy, set to launch in January at a starting price of 149 USD per month [7] - ZIM Integrated Shipping Services (ZIM.US) rose 5.78% as the board evaluates multiple acquisition proposals from strategic investors [7]

启明医疗-B(02500)涨超4%，截至发稿，涨4.64%，报2.48港元，成交额115.62万港元。 消息面上，启明医疗发布公告称，于近日，集团已就Cardiovalve经导管三尖瓣置换系统(Cardiovalve系 统)正式向欧洲公告机构递交CE MDR认证的全部申请资料。这标志着该产品在欧洲市场的准入进程迈 出关键一步。 Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相 比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约 95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简 单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。 ...

Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相 比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约 95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简 单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。 智通财经APP讯，启明医疗-B(02500)发布公告，于近日，集团已就Cardiovalve经导管三尖瓣置换系统 (Cardiovalve系统)正式向欧洲公告机构递交CE MDR认证的全部申请资料。 ...

格隆汇12月24日丨启明医疗-B(02500.HK)发布公告，近日，集团已就Cardiovalve经导管三尖瓣置换系统 ("Cardiovalve系统")正式向欧洲公告机构递交CEMDR认证的全部申请资料。 Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相 比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约 95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简 单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。 ...

Cardiovalve系统是一款同时可用于治疗二尖瓣反流和三尖瓣反流的经导管介入置换产品。与同类产品相 比，Cardiovalve系统经股静脉的入路方式显著提升了治疗安全性，产品最大55mm的大瓣环设计适用约 95%的患者群体，同时，其独特的短瓣架设计可有效降低心室流出道梗阻风险。Cardiovalve系统操作简 单、安全、可复制性强，只需定位、锚定、释放三个步骤完成。 启明医疗-B(02500)发布公告，于近日，集团已就Cardiovalve经导管三尖瓣置换系统(Cardiovalve系统)正 式向欧洲公告机构递交CE MDR认证的全部申请资料。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 杭州啓明醫療器械股份有限公司 Venus Medtech (Hangzhou) Inc. （股份代號：2500） （於中華人民共和國註冊成立的股份有限公司） 自願性公告 CARDIOVALVE三尖瓣置換遞交CE MDR認證申請 本 公 告 乃 由 杭 州 啓 明 醫 療 器 械 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 作 出，為 本 公 司 股 東 及 潛 在 投 資 者 提 供 有 關 本 集 團 最 新 業 務 發 展 及 新 產品研發進度的更新資料。 本 公 司 董 事（「董 事」）會（「董事會」）欣 然 宣 佈，於 近 日，本 集 團 已 就Cardiovalve經 導 管 三 尖 瓣 置 換 系 統（「Cardiovalve系 統」）正 式 向 歐 洲 公 告 機 構 遞 交CE ...